Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Innovent Biologics Inc (1801)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
91.25 -0.15    -0.16%
08/08 - Closed. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  KYG4818G1010 
  • Volume: 18,274,901
  • Bid/Ask: 91.10 / 91.30
  • Day's Range: 89.60 - 93.20
Innovent Biologics 91.25 -0.15 -0.16%

Innovent Biologics Inc Company Profile

 
Get an in-depth profile of Innovent Biologics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

5659

Equity Type

ORD

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.

Contact Information

Address 168 Dongping Street Suzhou Industrial Park
Suzhou, 215123
China
Phone 86 512 6956 6088
Fax 86 512 6956 6088

Top Executives

Name Age Since Title
De-Chao Yu 60 2011 Co-Founder, Chairman & CEO
Qian Zhang 37 2024 Executive Director
Charles Leland Cooney 80 2015 Member of CMC Strategic Advisory Board & Independent Non-Executive Director
I-Yin Hsu 49 2018 Independent Non-Executive Director
Carlos Garcia-Echeverria 60 2021 Member of Scientific Advisory Board
Gary J. Zieziula 70 2022 Independent Non-Executive Director
Chiang Syin 69 - Member of CMC Strategic Advisory Board
David LaPre 73 - Member of CMC Strategic Advisory Board
Lewis L. Lanier - 2021 Member of Scientific Advisory Board
Lawrence Fong - 2021 Member of Scientific Advisory Board
Erwin Vanhaecke - - Member of CMC Strategic Advisory Board
Shuyun Chen 50 2024 Lead Independent Non-Executive Director
Qian Zhang 38 2019 Chief People Officer, GM & Executive Director
Hao Xi Ede 66 2024 Executive Director & Fund Managing Partner
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

1801 Comments

Write your thoughts about Innovent Biologics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email